Company / SG&A Expense
Royalty Pharma plc SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$573.5M
FY2025
5-year range
$103.4M / $573.5M
FY2021-FY2025
Trend
+142.3%
vs FY2024
Sector context
#30 of 213
Health Care
What the data says
Royalty Pharma plc's sg&a expense of $573M is higher than 86% of companies in the Health Care sector (FY2025). SG&A Expense has fluctuated over the past 8 years, ranging from $62M in FY2020 to $573M in FY2025.
Based on SEC 10-K filings.
$573M in FY2025 with a 5-year CAGR of +56.1%. Top quartile in the Health Care sector.
Increased from $250M to $573M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +46.7%
- 5-Year CAGR
- +56.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 213This company $573.5M Sector average $722.3M
▼
-20.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +56.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 142.3% year-over-year.
- Ranks #30 out of 213 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- Strong profit margin: 38.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $573.5M | +142.3% |
| FY2024 | $236.7M | -5.2% |
| FY2023 | $249.7M | +37.4% |
| FY2022 | $181.7M | +75.7% |
| FY2021 | $103.4M | +67.1% |
| FY2020 | $61.9M | -40.2% |
| FY2019 | $103.4M | +67.1% |
| FY2018 | $61.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026